Pacific Biosciences of California Long Term Debt

As of the most recent data (June 2026), PACB shows a long-term debt of $700M. That compares with $700M in the prior-year period — up 0.9% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, PACB's long-term debt is now $700M (was $700M) — a 0.9% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Pacific Biosciences of California is outperforming or lagging.

Tracking PACB's long-term debt over time shows whether Pacific Biosciences of California is scaling, shrinking, or reshaping that part of the business. The current reading is $700M That compares with $700M in the prior-year period — up 0.9% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this long-term debt page, Stockcircle has Pacific Biosciences of California's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect long-term debt (currently $700M) with ownership activity and broader fundamentals.

Pacific Biosciences of California's long-term debt is $700M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.